Thompson Elizabeth H.Z. 4

What Happened
Elizabeth H.Z. Thompson, EVP and Head of Research & Development at ACADIA Pharmaceuticals (ACAD), received two awards on March 6, 2026: 101,574 derivative securities reported as a grant (stock option-type award) and 29,548 restricted stock units (RSUs). Both awards were reported at an acquisition price of $0.00 in the filing — these are compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: March 6, 2026; Filing date: March 10, 2026 (filed within the usual SEC 2-business-day window).
• Award amounts and prices: 101,574 derivative securities @ $0.00; 29,548 RSUs @ $0.00.
• Shares owned after transaction: Not disclosed in the provided filing summary.
• Footnotes / vesting:
  • F1 (options): 25% of the option shares vest on March 6, 2027; remaining option shares vest in 36 equal monthly installments thereafter.
  • F2 (RSUs): Each RSU represents a contingent right to one share of common stock.
  • F3 (RSU vesting): RSUs vest in four equal annual installments beginning March 6, 2027.
• Transaction type code: A = Award/Grant (not a sale or purchase).

Context
These are standard compensation grants to an executive—options (derivative awards) and RSUs—that create the right to receive shares in the future if vesting conditions are met. No exercise or sale occurred in this filing, and awards reported at $0 reflect grant reporting rather than cash outlay or market trades.